Arizona State Retirement System Decreases Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Arizona State Retirement System cut its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 8.9% during the 4th quarter, HoldingsChannel reports. The fund owned 10,607 shares of the company’s stock after selling 1,041 shares during the quarter. Arizona State Retirement System’s holdings in Kiniksa Pharmaceuticals were worth $210,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Wellington Management Group LLP purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $1,192,000. JPMorgan Chase & Co. purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $4,997,000. Parkman Healthcare Partners LLC increased its stake in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after buying an additional 108,102 shares during the period. Segall Bryant & Hamill LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $675,000. Finally, SG Americas Securities LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth $355,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $37.17.

Insider Activity

In other news, CFO Mark Ragosa sold 36,372 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the sale, the chief financial officer now owns 22,958 shares in the company, valued at approximately $510,815.50. The trade was a 61.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $18.24, for a total transaction of $255,360.00. Following the completion of the transaction, the chief operating officer now owns 88,975 shares in the company, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 73,423 shares of company stock worth $1,541,812. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Trading Up 2.0 %

Shares of Kiniksa Pharmaceuticals stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The company has a market cap of $1.64 billion, a P/E ratio of -161.49 and a beta of 0.48. The company’s fifty day simple moving average is $19.99 and its two-hundred day simple moving average is $22.16.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same quarter last year, the firm posted $0.35 EPS. The business’s quarterly revenue was up 46.9% on a year-over-year basis. Analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.